Edition:
India

Athersys Inc (ATHX.OQ)

ATHX.OQ on NASDAQ Stock Exchange Capital Market

2.01USD
8:47pm IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.01
Open
$2.00
Day's High
$2.01
Day's Low
$1.97
Volume
40,377
Avg. Vol
127,830
52-wk High
$2.62
52-wk Low
$1.29

Latest Key Developments (Source: Significant Developments)

Athersys Reports Q4 Revenue $1.2 Million Versus $1.0 Million
Wednesday, 14 Mar 2018 

March 13 (Reuters) - Athersys Inc ::ATHERSYS REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER, FULL YEAR 2017.Q4 REVENUE $1.2 MILLION VERSUS $1.0 MILLION.Q4 REVENUE VIEW $417,000 -- THOMSON REUTERS I/B/E/S.QTRLY LOSS PER SHARE $0.11‍​.  Full Article

Athersys and Healios announce binding letter of intent to expand multistem collaboration
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Athersys Inc ::ATHERSYS AND HEALIOS ANNOUNCE BINDING LETTER OF INTENT TO EXPAND MULTISTEM® COLLABORATION.CO, HEALIOS K.K. ANNOUNCED INTENT TO SIGNIFICANTLY EXPAND THEIR EXISTING DEVELOPMENT AND COMMERCIALIZATION COLLABORATION​.WOULD RECEIVE COMMITTED PAYMENTS OF $35 MILLION, AS WELL AS ADDITIONAL PAYMENTS, INCLUDING MILESTONES AND ROYALTIES..ATHERSYS- ‍AS PART OF THIS EXPANSION, HEALIOS IS MAKING AN APPROXIMATE $21 MILLION EQUITY INVESTMENT AT $1.76 PER SHARE, WILL DEPOSIT $10 MILLION INTO ESCROW​.‍HEALIOS WILL OBTAIN EXCLUSIVE OPTION TO LICENSE TO COMMERCIALIZE MULTISTEM PRODUCTS FOR ISCHEMIC STROKE, ARDS AND TRAUMA IN CHINA​.DR. HARDY KAGIMOTO, CEO OF HEALIOS, WOULD BE NOMINATED FOR ELECTION TO ATHERSYS BOARD AT NEXT ANNUAL MEETING IN JUNE 2018.WILL PAY AN ADDITIONAL $25 MILLION IN LICENSE/OPTION FEES, IN INSTALLMENTS.  Full Article

Athersys Says On Feb 1, Co Entered Into Common Stock Purchase Agreement With Aspire Capital Fund
Friday, 2 Feb 2018 

Feb 1 (Reuters) - Athersys Inc ::ATHERSYS INC SAYS ON FEB 1, CO ENTERED INTO COMMON STOCK PURCHASE AGREEMENT WITH ASPIRE CAPITAL FUND - SEC FILING.ATHERSYS INC - AS PER COMMON STOCK PURCHASE AGREEMENT, ASPIRE CAPITAL COMMITTED TO PURCHASE UP TO AGGREGATE OF $100 MILLION OF SHARES OF CO'S COMMON STOCK.  Full Article

Athersys reports Q3 loss per share $0.06
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Athersys Inc :Athersys reports third quarter 2017 results.Q3 loss per share $0.06.Q3 revenue $400,000 versus $300,000.Q3 revenue view $598,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.  Full Article

Athersys and Nikon Cell Innovation to collaborate on MultiStem manufacturing in Japan
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Athersys Inc ::Athersys and Nikon Cell Innovation to collaborate on multistem commercial manufacturing in Japan.Athersys - entered manufacturing services agreement with Nikon Cell for commercial production of its stem cell therapy in Japan for ischemic stroke.Athersys - technology transfer of stem cell production methods in preparation for potential commercialization in Japan after treasure clinical study.  Full Article

Athersys Q2 loss per share $0.06
Thursday, 10 Aug 2017 

Aug 9 (Reuters) - Athersys Inc :Athersys reports second quarter 2017 results.Q2 revenue $700,000 versus $600,000.Q2 loss per share $0.06.Q2 revenue view $554,000 -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S.  Full Article

Athersys reports alignment of key regulators for pivotal registration study in stroke
Monday, 7 Aug 2017 

Aug 7 (Reuters) - Athersys Inc :Athersys reports alignment of key regulators for pivotal registration study in stroke.Athersys Inc - in Japan, Athersys' partner, Healios K.K. is conducting treasure study, evaluating multistem therapy for ischemic stroke.Athersys - design of phase 3 clinical study treating ischemic stroke with multistem cell therapy product received a final scientific advice positive opinion from EMA.Athersys - treasure study has received a priority review designation under Sakigake from Japan's pharmaceutical and medical devices agency.Athersys - results from treasure study are acceptable for supporting applications for registration, along with results from masters-2 study, in U.S., Europe.  Full Article

Athersys reports Q1 loss per share $0.06
Wednesday, 10 May 2017 

May 9 (Reuters) - Athersys Inc :Athersys reports first quarter 2017 results.Q1 revenue $1.5 million versus $15.5 million.Q1 loss per share $0.06.Q1 revenue view $638,000 -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S.  Full Article

Athersys Inc files for mixed shelf offering of up to $75 mln
Saturday, 11 Mar 2017 

Athersys Inc :Athersys Inc files for mixed shelf offering of up to $75 million - sec filing.  Full Article

Athersys reports pricing of public offering of common stock
Friday, 27 Jan 2017 

Athersys Inc :Athersys announces pricing of public offering of common stock.  Full Article

BRIEF-Uthealth In Houston And Athersys Announce Funding For Clinical Trial Using Multistem® To Treat Trauma Patients

* UTHEALTH IN HOUSTON AND ATHERSYS ANNOUNCE FUNDING FOR CLINICAL TRIAL USING MULTISTEM® TO TREAT TRAUMA PATIENTS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)